GEN2 was evaluated in adult patients with advanced solid tumors in an intravenous dose escalation Phase 1 study GEN2 is well-tolerated, with no Dose Limiting Toxicity or treatment-related ...

Nouscom Presents New Positive Phase 1/2b data of NOUS-209 at SITC 2025, Supporting Plans to Initiate Registration-Enabling Study for Cancer ...

ELATIVE long-term open label extension trial demonstrate sustained biochemical response, stabilization of fibrosis markers ...

A2 Biotherapeutics, Inc. (A2 Bio), a clinical-stage cell therapy company developing first-in-class logic-gated cell therapies for solid tumors, today announced the presentation of safety and early ...

Meta documents reveal the company projected earning billions from scam ads, failing for years to stop fraudulent schemes ...

Phase 1b data demonstrating favorable safety and tolerability profile and potent reductions in viral nucleic acids highlighted in late-breaking poster presentation - ...

Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and precision oncology, today announced the presentation of three studies at the Society for Immunotherapy of Cancer (SITC) 40th ...

Immix Biopharma, Inc. is building strength in its pipeline with impressive early signals in AL amyloidosis. Learn more about ...

Viking Therapeutics captured investor attention with compelling new research findings for its obesity treatment candidate VK2735. The biopharmaceutical company unveiled detailed results from its ...

TTM Technologies' double-digit growth and industry tailwinds suggest further upside, with future revenue growth not fully ...

Explore the idea of a single, secure digital identity for accessing all government services. Learn about the technical challenges, security, and user experience considerations.

A four-month investigation with Channel 4 News reveals harrowing failings at one of Britain's most prestigious hospitals ...